UK trial starts for BPH (benign prostatic hyperplasia) ethanol injection therapy:
This article was originally published in Clinica
UK researchers have begun a trial to assess American Medical Systems' (AMS) ProstaJect minimally invasive ethanol injection system for treating benign prostatic hyperplasia. Some 20 patients will be treated in the study led by Mr John Palmer of the Medway Maritime Hospital in Kent. Minneapolis, Minnesota-based AMS is also expanding the trial to include 250 patients in six additional European countries over the next six months. The company said that the ProstaJect procedure can be performed in as little as 20 minutes under a local anaesthetic.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.